Literature DB >> 16180724

Ataxia-telangiectasia genes and breast cancer risk in a French family study.

Nadine Andrieu1, Eve Cavaciuti, Anthony Laugé, Katia Ossian, Nicolas Janin, Janet Hall, Dominique Stoppa-Lyonnet.   

Abstract

Ataxia-telangiectasia (AT) is a rare autosomal recessive early childhood disorder, characterized by progressive neuronal degeneration, immunological deficiency, radiosensitivity and an increased risk of cancer caused in most cases by mutations in the AT-mutated gene (ATM). Epidemiological studies on AT families have shown that AT heterozygous women have an increased risk of developing breast cancer (BC). The ATM protein plays a central role in the recognition and repair of DNA double-strand breaks and the subsequent activation of cell-cycle checkpoints. Whilst AT is a rare disease, 0.5-1 % of the general population are estimated to be AT mutation carriers, thus any increases in the risks of cancer associated with ATM carrier status are of public health relevance. The main results of our published studies on the risk of BC in 34 French AT families according to heterozygote status, type of ATM mutation and exogenous factors are summarized here. The risk of BC was higher in ATM heterozygous (HetATM) women and did not differ significantly according to the type of ATM mutation (missense vs truncating) carried by the AT family members but appeared associated with the position of some truncating mutations in certain binding domains of the ATM protein. The effect of exogenous factors, such as reproductive life factors and exposure to ionizing radiation, on the risk of BC according to ATM heterozygote status was assessed. There was no evidence for interaction (except for age at first full-term pregnancy). These findings does not appear to justify a separate screening program from that already available to other women with a first-degree relative affected by BC, as their risks have similar amplitude. Chest X-rays did not appear to be a risk factor for BC in our study population. More powerful studies, using data sets pooled from international sources are being set up to confirm these observations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16180724     DOI: 10.1017/s0022029905001147

Source DB:  PubMed          Journal:  J Dairy Res        ISSN: 0022-0299            Impact factor:   1.904


  5 in total

1.  Gene expression signatures but not cell cycle checkpoint functions distinguish AT carriers from normal individuals.

Authors:  Liwen Zhang; Dennis A Simpson; Cynthia L Innes; Jeff Chou; Pierre R Bushel; Richard S Paules; William K Kaufmann; Tong Zhou
Journal:  Physiol Genomics       Date:  2013-08-13       Impact factor: 3.107

2.  Mechanisms of increased risk of tumorigenesis in Atm and Brca1 double heterozygosity.

Authors:  Jufang Wang; Fengtao Su; Lubomir B Smilenov; Libin Zhou; Wentao Hu; Nan Ding; Guangming Zhou
Journal:  Radiat Oncol       Date:  2011-08-17       Impact factor: 3.481

3.  Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.

Authors:  Anne-Laure Renault; Noura Mebirouk; Laetitia Fuhrmann; Guillaume Bataillon; Eve Cavaciuti; Dorothée Le Gal; Elodie Girard; Tatiana Popova; Philippe La Rosa; Juana Beauvallet; Séverine Eon-Marchais; Marie-Gabrielle Dondon; Catherine Dubois d'Enghien; Anthony Laugé; Walid Chemlali; Virginie Raynal; Martine Labbé; Ivan Bièche; Sylvain Baulande; Jacques-Olivier Bay; Pascaline Berthet; Olivier Caron; Bruno Buecher; Laurence Faivre; Marc Fresnay; Marion Gauthier-Villars; Paul Gesta; Nicolas Janin; Sophie Lejeune; Christine Maugard; Sébastien Moutton; Laurence Venat-Bouvet; Hélène Zattara; Jean-Pierre Fricker; Laurence Gladieff; Isabelle Coupier; Georgia Chenevix-Trench; Janet Hall; Anne Vincent-Salomon; Dominique Stoppa-Lyonnet; Nadine Andrieu; Fabienne Lesueur
Journal:  Breast Cancer Res       Date:  2018-04-17       Impact factor: 6.466

Review 4.  First international workshop of the ATM and cancer risk group (4-5 December 2019).

Authors:  Fabienne Lesueur; Douglas F Easton; Anne-Laure Renault; Sean V Tavtigian; Jonine L Bernstein; Zsofia Kote-Jarai; Rosalind A Eeles; Dijana Plaseska-Karanfia; Lidia Feliubadaló; Banu Arun; Natalie Herold; Beatrix Versmold; Rita Katharina Schmutzler; Tú Nguyen-Dumont; Melissa C Southey; Leila Dorling; Alison M Dunning; Paola Ghiorzo; Bruna Samia Dalmasso; Eve Cavaciuti; Dorothée Le Gal; Nicholas J Roberts; Mev Dominguez-Valentin; Matti Rookus; Alexander M R Taylor; Alisa M Goldstein; David E Goldgar; Dominique Stoppa-Lyonnet; Nadine Andrieu
Journal:  Fam Cancer       Date:  2021-06-14       Impact factor: 2.375

5.  Telomere length, ATM mutation status and cancer risk in Ataxia-Telangiectasia families.

Authors:  Anne-Laure Renault; Noura Mebirouk; Eve Cavaciuti; Dorothée Le Gal; Julie Lecarpentier; Catherine Dubois d'Enghien; Anthony Laugé; Marie-Gabrielle Dondon; Martine Labbé; Gaetan Lesca; Dominique Leroux; Laurence Gladieff; Claude Adenis; Laurence Faivre; Brigitte Gilbert-Dussardier; Alain Lortholary; Jean-Pierre Fricker; Karin Dahan; Jacques-Olivier Bay; Michel Longy; Bruno Buecher; Nicolas Janin; Hélène Zattara; Pascaline Berthet; Audrey Combès; Isabelle Coupier; Janet Hall; Dominique Stoppa-Lyonnet; Nadine Andrieu; Fabienne Lesueur
Journal:  Carcinogenesis       Date:  2017-10-01       Impact factor: 4.944

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.